Progression of White Matter Lesion Volume and Health-Related Quality of Life in Patients with Symptomatic Atherosclerotic Disease: The SMART-MR Study

Table 1

Baseline characteristics of patients with complete data at followup and of those lost to followup.

	Complete data at followup (𝑛=486)	Lost to followup (𝑛=503)
Age^¥ (years)	58 ± 9.3	60 ± 10.2
Male gender (%)	80	79
Diagnosis of symptomatic atherosclerotic disease^‡
(i) Peripheral arterial disease	19	26
(ii) Coronary artery disease	65	61
(iii) Cerebrovascular disease	24	23
(iv) Abdominal aortic aneurysm	5	11
Severe atherosclerotic disease^£	11	9
Smoking^† (pack/years)	21 (0–53)	18 (0–50)
Alcohol use
(i) Never	13	18
(ii) Former	7	11
(iii) Current	79	72
Hypertension (%)	50	57
Diabetes mellitus (%)	16	25
Total intracranial volume^¥ (mL)	1467 ± 127	1457 ± 132
Absolute total WML volume^† (mL)	1.3 (0.4–5.8)	1.7 (0.6–8.3)
Physical functioning^†	44 (29–55)	43 (26–54)
Mental functioning^†	51 (32–60)	48 (29–60)

WML: white matter lesions; mRS: modified Rankin Scale.
^‡ The different groups of symptomatic atherosclerotic disease do not add up to the total study sample of 486, because various locations of symptomatic atherosclerotic disease can occur within one patient.
^£Defined as patients with coronary artery disease and three-vessel or left main disease at inclusion, patients with cerebrovascular disease and a mRS grade ≥2 at inclusion, or patients with peripheral arterial disease with Fontaine grade ≥3 at inclusion.
^¥ Mean ± SD
^† Median, (10th–90th percentile).